TD Cowen analyst Yaron Werber has reiterated their bullish stance on NUVB stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yaron Werber has given his Buy rating due to a combination of factors that highlight the positive trajectory of Nuvation Bio’s key products. The strong uptake of Ibtrozi, with 82 patients already on the drug and a steady addition of 2-3 new patients per business day, indicates a promising market penetration. This momentum is expected to continue, with projections suggesting a significant increase in patient numbers by the end of 2025. The ongoing head-to-head study in China and potential European partnerships further bolster the drug’s prospects.
Additionally, the development of Safusidenib for high-risk glioma is progressing well, with a Phase 2 readout anticipated by the end of 2025. The updated trial design and ongoing discussions with the FDA regarding the Phase 3 trial underscore the potential for future success. These factors, combined with increased revenue projections for Ibtrozi, contribute to Werber’s optimistic outlook and Buy rating for Nuvation Bio.
In another report released today, Wedbush also maintained a Buy rating on the stock with a $6.00 price target.